June 24, 2022
1 min watch
Save
VIDEO: Study queries association between HSD3B1 genotype and prostate cancer outcomes
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Nima Sharifi, MD, director, Center for GU Malignancies Research, Lerner Research Institute, Cleveland Clinic, discusses a new study regarding metastatic prostate cancer presented at ASCO Annual Meeting.
Sharifi introduces the study, which examined the association of the HSD3B1 genotype with outcomes in metastatic hormone-sensitive prostate cancer treated with androgen deprivation therapy.
Sharifi also discussed the parameters in the study and the inspiration behind it, which involved curiosity behind the effect of enzalutamide.
Reference:
- Sharifi N. The association of germline HSD3B1 genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES]. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Sharifi reports consulting for Roivant Sciences and receiving research funding from Astellas Pharma and Bristol Myers Squibb Foundation.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.